SAba Sile
Corporate Officer/Principal bei SPRUCE BIOSCIENCES, INC.
Profil
SAba Sile is currently the Vice President-Clinical Development at Spruce Biosciences, Inc. Prior to this, Sile worked as a Medical Director at BioMarin Pharmaceutical, Inc. and as an Executive Medical Director-Clinical Development at Horizon Therapeutics Plc.
Sile holds a doctorate degree from the University of Pittsburgh School of Medicine.
Aktive Positionen von SAba Sile
| Unternehmen | Position | Beginn |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Corporate Officer/Principal | 10.11.2022 |
Ehemalige bekannte Positionen von SAba Sile
| Unternehmen | Position | Ende |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | - |
Ausbildung von SAba Sile
| University of Pittsburgh School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
